Are You A Candidate For Breast Cancer Testing?
Because breast cancer is one of the most common cancers, many individuals are becoming aware of genetic testing for BRCA mutations. BRCA testing is not appropriate for most people.
If you think there's a possibility that your family has a hereditary cancer pattern, talk to a genetic counselor. The genetic counselor will assess the likelihood for you to carry a cancer predisposition mutation and, if indicated, discuss the option of genetic testing.
You might want to seek genetic counseling and breast and ovarian cancer risk assessment if you have one of the following:
- Breast cancer at an early age
- Two primary breast cancers or breast cancer and an incidence of ovarian, fallopian tube or primary peritoneal cancer
- Two or more primary breast cancers or breast cancer and ovarian, fallopian tube or primary peritoneal cancers in one or more close relatives from the same side of the family (maternal or paternal)
- A combination of breast cancer with one or more of the following: thyroid cancer, sarcoma, adrenocortical carcinoma, endometrial cancer, pancreatic cancer, brain tumors, diffuse gastric cancer, dermatological manifestations or leukemia/lymphoma on the same side of the family
- Member of the family with a known mutation in a cancer susceptibility gene
- Any male breast cancer
- Any ovarian, fallopian tube or primary peritoneal cancer
Your ethnic background may come into play with breast cancer risk as well, if you are of Ashkenazi Jewish descent. Women with such a background are about 10 times more likely to have a mutation than women in the general population. If you are of Ashkenazi Jewish descent, you may also consider genetic counseling if there is any family history of breast or ovarian cancer. An Ashkenazi Jewish BRCA testing panel is available. This test looks for three specific mutations that account for 90 percent of the positive BRCA1/2 gene changes in this population. If the test is negative, BRCA sequence analysis may be ordered.
As you think about your family history, keep in mind that these mutations can be inherited maternally or paternally. Be sure to look at your father's family history, in addition to your mother's.
It is important to remember that even when a family has a mutation, not everyone will inherit it. For example, if your father carries a BRCA1 mutation , he still has an unaffected copy of BRCA1. It depends on which gene is inherited by each child, and there is a 50 percent chance that each child will inherit the BRCA mutation. Thus, in a group of siblings, some may inherit a mutation, while others may not.
BRCA testing has several limitations. Not all families that have cancers consistent with a BRCA mutation will test positive. This is because it is believed that there are other genes involved with breast and ovarian cancer risk. It is suspected that approximately 16 percent of HBOC families have mutations in genes other than BRCA1 and BRCA2 . For this reason, it is ideal to test the person in the family who is most likely to test positive, to confirm whether a mutation can be identified. Another limitation of this test is that sometimes people receive an "uncertain" result. No matter whether the result is positive, negative or uncertain, your genetic counselor will thoroughly explain the results and what it means for you and your cancer risk.
There are several other cancer syndromes that have breast cancer as a feature. For this reason, the family history information is crucial. It can greatly change what gene may be suspected. Pathology reports, medical records and even death certificates can be useful for your genetic counselor.
Several variations of BRCA testing are available. Your genetic counselor can help determine which is most appropriate.
Comprehensive sequence analysis of BRCA1 and BRCA2 costs about $3,120. If a mutation is identified in the first person tested, subsequent tests for other family members are approximately $440 each. The reason the first test is so expensive is that the genes must be fully sequenced to identify the mutation. Once a mutation is found, the technicians know where exactly to look in the other relatives' DNA samples. Those of Ashkenazi Jewish descent (Eastern European background) may be tested using the BRCA Ashkenazi panel, examining three specific mutations most commonly found in this population, which costs approximately $535. A new addition to BRCA testing became available in 2006. This test looks for large deletions and duplications of the BRCA genes. This test is called BART and costs $650.
Again, it is important to regularly contact your genetic counselor to update your family history. New genetic testing becomes available over time. Also, learning of additional family members and their cancers may change your genetic assessment and lead to considering testing for a different gene.
If no one in your family has been diagnosed with breast or ovarian cancer, then your risk of carrying a BRCA1/2 mutation is quite low and testing would not be recommended. Keep in mind, however, that absence of these mutations doesn't mean you won't develop cancer. At least 90 percent of breast and ovarian cancer cases are "sporadic," meaning they don't stem from inherited mutations, but rather are caused by a mutation or a combination of mutations that arise over time. Therefore, regardless of your genetic status, be sure to follow the recommendations of your health care professional, such as having an annual breast examination by your health care professional (called a clinical breast examination) and a mammogram, if appropriate (schedule based on age).
Finally, if you test negative, you should still be assessed for cancer risk, based on your family history and medical history. This information can help determine whether you are at average risk, using general screening guidelines, or whether your screening regimen should be tailored to you.
Did You Test Positive?
If you test positive for a BRCA mutation, there are options for minimizing your cancer risk, but none of them reduce your risk to zero. No individuals are the same, and you should ask your health care professional to help you weigh the risks and benefits for each of the following options.
- Breast self-exam training and education, starting monthly breast self-exams at age 18.
- Clinical breast exam, semiannually, starting at age 25.
- Annual mammogram and breast MRI starting at age 25.
- Risk-reducing mastectomy.
- Risk-reducing salpingo-oophorectomy (removal of ovaries and fallopian tubes), ideally between 35 and 40 years old, or upon completion of child bearing, or individualized based on earliest age of onset of ovarian cancer in the family.
- For those who have not elected salpingo-oophorectomy, concurrent transvaginal ultrasound and CA-125 (a blood test that may indicate certain cancers) every six months starting at age 35, or 5 to 10 years earlier than the earliest age of diagnosis of ovarian cancer in the family.
- Chemoprevention options, such as tamoxifen and raloxifene. These medications are typically used after breast cancer to reduce the risk for another breast cancer, but in high-risk individuals, they can be offered to reduce the risk for an initial breast cancer.
- Investigational imaging and screening studies, when available.
Oophorectomy is increasingly being recommended for women who test positive for BRCA mutations and are either finished with childbearing or are certain that they do not want children. Removal of the ovaries not only reduces ovarian cancer risk 80 percent or more in both pre- and post-menopausal women, it also reduces breast cancer risk 50 percent in premenopausal women. That's because the ovaries produce estrogen, which stimulates breast growth and is linked to cancer risk. Removing the ovaries also removes your body's source of estrogen. Therefore, estrogen levels diminish rapidly and trigger menopausal symptoms, such as hot flashes, vaginal dryness and bone loss, among other short-term physical and emotional changes and long-term health risks associated with menopause. For some women, "surgical menopause," through removal of the ovaries, can trigger more sudden and severe menopausal symptoms than when menopause occurs spontaneously at the end of a woman's childbearing years—a transition that typically takes about five years in a woman's late 40s.
Postmenopausal hormone therapy (often referred to as hormone replacement therapy or HRT) can be prescribed prior to or just after surgery to mitigate menopausal symptoms. However, women, health care professionals and the federal government are scrutinizing the use of postmenopausal hormone therapy more closely than ever before and its safety for both long-term and short-term use is in question.
The U.S. Food and Drug Administration (FDA) now requires a highlighted and boxed warning on all estrogen projects for use by postmenopausal women. The so-called "black box" is the strongest step the FDA can take to warn consumers of potential risks from a medication. The warning highlights the increased risk for heart disease, heart attacks, stroke and breast cancer from supplemental estrogen—risks illuminated by part of the Women's Health Initiative study, which was abruptly halted when the risks were identified.
The "black-box" warning also advises health care professionals to prescribe estrogen products at the lowest dose and for the shortest possible length of time. Women taking estrogen projects are cautioned to have yearly breast exams and receive periodic mammograms.
Because every woman's risk profile is different, women who are thinking about taking postmenopausal hormone therapy or are currently taking it, need to review their options and treatment plans with their health care professional in light of the FDA's warning.
Since then, new lower-dose versions of the hormone therapies used to treat symptoms of menopause have been developed. The FDA approved a low-dose version of the combination estrogen-progestin treatment Prempro and the estrogen-only Premarin.